No Data
Evercore Initiates Benitec Biopharma(BNTC.US) With Buy Rating, Announces Target Price $25
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Benitec Biopharma | 10-K/A: Annual report (Amendment)
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development...
Benitec Biopharma Shares Are Trading Higher After the Company Announced Oculopharyngeal Muscular Dystrophy Patients Treated With BB-301 Experienced Improvements in Throat Closure, Throat Emptying, and Total Dysphagic Symptom Burden.
Express News | Benitec Biopharma Announces Positive Interim Phase 1B/2a Results for High Dose Bb-301 and Continued Durable Improvements for Low Dose Bb-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference